OncoMed Pharmaceuticals Granted Additional Broad Anti-RSPO Antibody Patent in U.S.
September 25, 2013 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 25, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
OncoMed Pharmaceuticals to Present Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013 (ECC 2013)
September 23, 2013 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
Updated clinical data to be presented for vantictumab at ECC 2013
Vantictumab, a program partnered with Bayer Pharma AG, is advancing to three combination Phase 1b studies in selected tumor...
OncoMed Pharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
September 20, 2013 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 20, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizumab (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer
September 19, 2013 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 19, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
OncoMed Pharmaceuticals Announces Second Quarter 2013 Financial Results
September 03, 2013 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
Company Completes $94 Million IPO in July
Vantictumab Dose Escalation Progress Triggers $10 Million Milestone in August
REDWOOD CITY, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- OncoMed...
OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)
August 22, 2013 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 22, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
OncoMed Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
July 23, 2013 11:39 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., July 23, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), today announced the closing of its initial public offering of 5,520,000 shares of its common stock...
OncoMed Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
July 17, 2013 20:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), today announced the pricing of its initial public offering of 4,800,000 shares of its common stock...